Pancreatic Cancer Metastatic Clinical Trial
Official title:
Real-world Evidence on Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)
The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI
The objectives on patients still alive one year after the first cycle of nal-IRI : - Characterize mPDAC patient population according to their demographics - Identify PDAC treatment by line of treatment from diagnosis to last treatment - Explore prognostic factors of longer Overall Survival (OS) and Progression Free Survivor (PFS) among mPDAC patients showing long-term Survival ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05047991 -
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04469556 -
Pancreatic Adenocarcinoma Signature Stratification for Treatment
|
Phase 2 | |
| Completed |
NCT03504423 -
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
|
Phase 3 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04799431 -
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
|
Phase 1 | |
| Recruiting |
NCT04674956 -
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03412799 -
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
|
Phase 1 | |
| Withdrawn |
NCT04852367 -
PanDox: Targeted Doxorubicin in Pancreatic Tumours
|
Phase 1 | |
| Recruiting |
NCT04467593 -
Safety Study of Whole Body Hyperthermia for Advanced Cancer
|
N/A | |
| Recruiting |
NCT02959151 -
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
|
Phase 1/Phase 2 | |
| Completed |
NCT01652976 -
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT04721301 -
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
|
Phase 1 | |
| Recruiting |
NCT04667403 -
Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT06168812 -
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06076837 -
The Seven Trial: Exploiting the Unfolded Protein Response
|
Phase 1 | |
| Active, not recruiting |
NCT03984214 -
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05254171 -
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04116073 -
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
|
Phase 2 | |
| Recruiting |
NCT04338763 -
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06030622 -
Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
|
Phase 1/Phase 2 |